Invetx Raises $60.5M in Series B Funding
Summary
Invetx, a Boston, MA-based pioneer in protein-based therapeutics for animal health, raised $60.5m in Series B financing. The company intends to use the funds to advance its monoclonal antibody (mAb) pipeline and pursue market approvals for therapeutics targeting chronic and serious diseases in dogs and cats. Led by Juergen Horn, PhD, chief executive officer, Invetx has built an integrated, iscovery, development, and manufacturing platform to create fully species-specific, optimized and half-life extended product candidates. By leveraging validated biotechnologies from human health and optimizing them for application in veterinary medicine, the company can generate differentiated antibodies to treat a wide variety of chronic and serious diseases in animals. Invetx has a broad pipeline of biotherapeutics in various therapeutic areas and expects to advance multiple candidates in development with product approvals anticipated potentially as early as 2025.